

Jennifer J Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/531273/publications.pdf>

Version: 2024-02-01

46
papers

1,705
citations

394421

19
h-index

289244

40
g-index

50
all docs

50
docs citations

50
times ranked

3178
citing authors

#	ARTICLE	IF	CITATIONS
1	A Smartphone-Based Model of Care to Support Patients With Cardiac Disease Transitioning From Hospital to the Community (TeleClinical Care): Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2022, 10, e32554.	3.7	27
2	HIIT for post-COVID patients within cardiac rehabilitation: Response to letter to the editor. International Journal of Cardiology, 2021, 322, 291-292.	1.7	4
3	Trials and Tribulations: mHealth Clinical Trials in the COVID-19 Pandemic. Yearbook of Medical Informatics, 2021, 30, 272-279.	1.0	6
4	Two case studies of cardiac arrest occurring in medically fit patients undergoing radical hysterectomy for cervical cancer. Gynecologic Oncology Reports, 2021, 37, 100823.	0.6	0
5	Process Evaluation of a Randomised Controlled Trial for TeleClinical Care, a Smartphone-App Based Model of Care. Frontiers in Medicine, 2021, 8, 780882.	2.6	4
6	High-intensity interval training for patients with coronary artery disease: Finding the optimal balance. International Journal of Cardiology, 2020, 298, 8-14.	1.7	21
7	Feasibility and Utility of a Cardiovascular Risk Screening Tool in Women Undergoing Routine Gynecology Evaluation. Journal of Women's Health, 2020, 29, 1150-1159.	3.3	6
8	Mobile Phone Technologies in the Management of Ischemic Heart Disease, Heart Failure, and Hypertension: Systematic Review and Meta-Analysis. JMIR MHealth and UHealth, 2020, 8, e16695.	3.7	45
9	Evaluation of an mHealth-Based Adjunct to Outpatient Cardiac Rehabilitation. IEEE Journal of Biomedical and Health Informatics, 2018, 22, 1938-1948.	6.3	27
10	High-Intensity Interval Training for Patients With Cardiovascular Disease—Is It Safe? A Systematic Review. Journal of the American Heart Association, 2018, 7, e009305.	3.7	128
11	Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	27
12	Reply: High Intensity Interval versus Moderate Intensity Continuous Training in Patients with Coronary Artery Disease. Heart Lung and Circulation, 2017, 26, 528-529.	0.4	1
13	Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention, 2017, 12, 1757-1765.	3.2	11
14	Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. Journal of the American College of Cardiology, 2016, 68, 2733-2744.	2.8	160
15	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	2.9	37
16	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. American Journal of Cardiology, 2016, 118, 1661-1668.	1.6	6
17	One-year results of the ICON (ionic versus non-ionic contrast to obviate worsening) Tj ETQq1 1 0.784314 rgBT /Over Cardiovascular Interventions, 2016, 87, 703-709.	1.7	9
18	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	2.1	3

#	ARTICLE	IF	CITATIONS
19	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 391-400.	1.7	8
20	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2016, 117, 192-200.	1.6	16
21	Incidence and Impact of Totally Occluded Culprit Coronary Arteries in Patients Presenting With Non-ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 428-433.	1.6	22
22	Gender-specific outcomes after balloon aortic valvuloplasty: Inhospital and long-term outcomes. <i>American Heart Journal</i> , 2015, 170, 180-186.	2.7	11
23	Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 359-368.	1.7	112
24	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. , 2015, , 2253-2270.		0
25	Chest Pain in Women: Evaluation and Management. , 2015, , 111-132.		0
26	Incidence and angiographic characteristics of patients With apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 343-348.	1.7	92
27	The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: A sub-analysis of the BRAVO study. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 148-153.	1.7	16
28	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. <i>European Heart Journal</i> , 2014, 35, 1533-1540.	2.2	210
29	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. <i>EuroIntervention</i> , 2014, 10, 312-319.	3.2	22
30	PCI Considerations in Women: Gender-Specific Outcomes and Challenges. , 2014, , 227-241.		0
31	Interventional Management of Diabetic Coronaropathy and Diffuse Coronary Artery Disease. , 2014, , 1-20.		0
32	Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2013, 111, 643-648.	1.6	71
33	Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction With Versus Without Previous Coronary Artery Bypass Grafting (from the Harmonizing Outcomes With) <i>Journal of Cardiology</i> . 2013, 111, 1377-1386.	1.6	23
34	Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. <i>American Journal of Cardiology</i> , 2013, 111, 196-201.	1.6	10
35	Coronary reperfusion and clinical outcomes after thrombus aspiration during primary percutaneous coronary intervention: Findings from the HORIZONS-AMI trial. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 594-601.	1.7	9
36	Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2013, 110, 118-123.	3.4	35

#	ARTICLE	IF	CITATIONS
37	B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 813-820.	3.9	41
38	The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2012, 1, 441-451.	0.4	0
39	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1231-1238.	2.9	32
40	Comparison of Abciximab Versus Eptifibatide During Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2012, 110, 940-947.	1.6	8
41	â€œCINâ€•No More: The Use of Contrast Volume to e-GFR Ratio to Predict and Prevent Contrast-Induced Acute Kidney Injury. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1201-1202.	1.7	1
42	Is There Attenuation of Benefit of Invasive Therapy in Patients with Chronic Kidney Disease? Results from Randomized Trials and Registry Data. <i>Current Cardiology Reports</i> , 2012, 14, 521-527.	2.9	4
43	Prognostic Significance of Postprocedural Sustained Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2012, 109, 805-812.	1.6	63
44	Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes With) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf of Cardiology</i> , 2012, 109, 831-838.	1.5	54
45	Impact of the Everolimus-Eluting Stent on Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1569-1577.	2.8	258
46	COMMENTARY: New Insights Into the Risk Factors of Contrast-Induced Encephalopathy. <i>Journal of Endovascular Therapy</i> , 2011, 18, 545-546.	1.5	60